30 October 2023
HeiQ Plc
("HeiQ" or "the Company")
Half year results for the period ended 30 June 2023
HeiQ Plc (LSE:HEIQ), a leading company in materials innovation and hygiene technologies, announces its interim results for the period ending 30 June 2023 ("H1 2023").
These results are published concurrently with the Company's final results for the full year ended 31 December 2022 ("FY 22").
Restoration of Trading:
As detailed in the FY 22 results, upon uploading the Annual Report 2022 to the National Storage Mechanism, expected to be completed today, the Company will make an immediate request to the FCA for the Company's Ordinary Shares to be restored to trading on the Main Market of the London Stock Exchange as soon as practicable thereafter. A further announcement will be made confirming the exact time and date of resumption of trading.
Financial Overview:
· Revenue reduced by 26% to US$20.5 million (H1 2022 restated*: US$27.6 million)
· Gross profit margin of 40.9% (H1 2022 restated*: 41.5% in H1 2022)
· Adjusted EBITDA of US-$3.6 million (H1 2022 restated*: US$0.7 million)
· Operating loss of US-$6.0 million (H1 2022 restated*: US-$1.6 million)
· Loss after taxation of US$-6.5 million (H1 2022 restated*: profit of US-$1.9 million)
· Cash balance as at 30 June 2023 of US$7.3 million
* Details on restatements of prior year financial information are disclosed in Note 2 of the Consolidated Financial Statements.
Operational Overview:
Trading conditions for the markets of our commercialized product range continued to be challenging during H1 2023 and, as highlighted in detail in our Full Year results for the 12 months to 31 December 2022, the Company took decisive steps to reduce its cost base and reorganize the business to maintain its innovation and differentiation capabilities during the period under review. With costs reduced and operations adapted in light of the challenging headwinds our entire industry is facing, the Company expects H2 2023 trading to stabilize.
Post Period:
The Company is closely monitoring the market and is ready to take further cost reduction action, should it need to. We continue to add value to our high potential key innovation initiatives through focused investment, to position ourselves for when the macro-economic difficulties abate.
While the Board considers the Company has adequate resources, it is in discussions with financial institutions to replace the currently uncommitted credit facilities by committed, long-term facilities.
Equity analyst and shareholder presentations:
Following the resumption of trading in its ordinary shares the Company will announce registration details for two live presentations. These presentations will cover today's results and will be held separately for both equity analysts and investors.
For further information, please contact:
HeiQ Plc Carlo Centonze (CEO) |
+41 56 250 68 50 |
Cavendish Securities Plc (Broker) Stephen Keys / Callum Davidson |
+44 (0) 207 397 8900 |
SEC Newgate (Media Enquiries) Elisabeth Cowell / Tom Carnegie / Molly Gretton |
+44 (0) 20 3757 6882 |
About HeiQ
HeiQ is a Swiss-based international company that innovates pioneering and differentiating materials in partnership with established global brands. We bridge the academic and commercial worlds to conceive performance-enhancing materials and technologies, working with aligned brands to research, manufacture and bring products to market, aiming for lab to consumer in months. Our goal is to improve the lives of billions by innovating the materials that go into everyday products, making them more hygienic, comfortable, protective, and sustainable.
Our strong IP portfolio positions us as an innovation leader for niche, premium and high-margin products in the textile chemicals, man-made fibers, paints and coatings, antimicrobial plastics, probiotics and household cleaner markets. We have also expanded into healthcare facilities, probiotic cleaning, and hygiene coatings markets to help make hospitals and healthcare environments more hygienic.
We have developed over 200 technologies in partnership with 300 major brands. With a substantial research and development pipeline, including key technology development projects HeiQ AeoniQ, HeiQ ECOS, HeiQ GrapheneX, and HeiQ Synbio, HeiQ aims to deliver shareholder value through sales growth and entry into new lucrative markets through disruptive innovation and M&A.
We have built a strong reputation for ESG & sustainable innovation, having won multiple awards including the Swiss Technology Award twice and the Swiss Environmental Award. Under experienced leadership, we are committed to driving our profit in close connection with people and the planet. For more information, please visit www.heiq.com.
Due to the delay in the publication of the audited annual accounts 2022, these interim financial statements 2023 are published at the same time as the annual accounts 2022.
While further details on trading and HeiQ's performance in H1 2023 can be found in the CEO Statement in the annual report 2022, I provide a short synopsis here for our investors.
Trading conditions for the markets of our commercialized product range continued to be challenging during H1 2023 and, as highlighted in detail in our Full Year results for the 12 months to December 31, 2022, we took focused steps to reduce our cost base and reorganize the business during the period under review.
We believe that the actions taken since the start of the year mean we will be better positioned to manage the challenging macro-economic environment, while continuing to build value in our core innovations to preserve our ability to deliver when the market demand turns.
Results |
Six months to |
Six months to |
Year ended |
|
|
June 30, 2023 |
June 30, 2022 |
December 31, 2022 |
|
|
US$'000 |
US$'000 |
US$'000 |
|
|
|
(restated*) |
|
|
Revenue |
20,500 |
27,558 |
47,202 |
|
Cost of sales |
(12,110) |
(16,127) |
(33,745) |
|
Gross profit |
8,390 |
11,431 |
13,457 |
|
Other income |
946 |
2,748 |
4,832 |
|
Selling and general administrative expenses |
(14,263) |
(14,016) |
(30,969) |
|
Impairment loss on intangible assets |
- |
- |
(11,651) |
|
Impairment loss on property, plant & equipment |
- |
- |
(730) |
|
Other expenses |
(1,075) |
(1,735) |
(4,184) |
|
Operating loss |
(6,002) |
(1,572) |
(29,245) |
|
Depreciation of property, plant and equipment |
710 |
644 |
1,282 |
|
Amortization of intangible assets |
1,069 |
666 |
1,435 |
|
Depreciation of right-of-use assets |
479 |
497 |
938 |
|
Impairment losses and write-offs |
- |
- |
13,278 |
|
Share options and rights granted to Directors and employees |
132 |
486 |
138 |
|
Adjusted EBITDA |
(3,612) |
721 |
(12,174) |
|
EBITDA Margin (adjusted) |
(17.6%) |
2.6% |
(25.8%) |
|
*The results have been restated in the comparative period as described in Note 2 to the consolidated financial statements.
Total revenues in H1 2023 decreased by 26% to US$20.5 million (H1 2022: US$ 27.6 million) driven by weak demand across the markets in which we operate.
Gross margin slightly decreased from 41.5% in H1 2022 to 40.9% in H1 2023, driven primarily by overcapacity in the markets which resulted in price pressure.
SG&A costs grew by 1.7% to US$14.3 million in H1 2023 compared to the previous year (H1 2022: US$14.0 million). The Company implemented various cost reduction measures during the period and expects to see the full benefit of the measures materialize in H2 2023. Cost saving measures have included a reduction of FTE's as well as re-location of functions/FTE's to locations with lower employer costs per FTE.
As of June 30, 2023, the Company reports a cash balance of US$7.3 million (December 31, 2022: US$8.5 million). To manage its cash balance, the Group has access to credit facilities totalling CHF9.0 million (approximately US$9.8 million as of September 30, 2023). The credit facilities are in place with two different banks and both contracts have materially the same conditions. The facilities are not limited in time, can be terminated by either party at any time and allow overdrafts and fixed cash advances with a duration of up to twelve months.
As of September 30, 2023, the Group has drawn CHF6.3 million of the facilities (CHF2.4 million as of December 31, 2022) (see Note 2 for details including maturity dates). The facilities are not committed, but the Board has not received any indication from financing partners that facilities are at risk of being terminated. Furthermore, the Board is in discussions with financial institutions to replace the currently uncommitted credit facilities by committed, long-term facilities, but the outcome of these discussions remains uncertain.
The Group's directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future and operate within its credit facilities for the period 12 months from date of signature. Nevertheless, the Board acknowledges the uncommitted status of the facilities which could be terminated requiring the refinancing of debts, and which casts material uncertainty on the going concern assessment until appropriate longer-term funding is in place. Further disclosures on the going concern assessment are made in the notes to the financial statements.
The Group has an established, structured approach to identifying and assessing the impact of financial and operational risks on its business. The principal risks and uncertainties for the remainder of the financial year are not expected to change materially from those included on pages 38 to 42 of the Annual Report and Accounts 2022. The risks identified relate to the following areas: Delivery on growth strategy; Increase in competition; Geographical risks; IP protection and first mover advantage; Regulatory risks; Reputational risks and failure to build brand equity; Innovation pipeline; Supply chain disruptions; Personnel/Workforce; Interruption of IT system operations; Liquidity risk; currency risks; Product liability. Further information in relation to the Group's financial position and going concern is included in note 2.
With our costs reduced and operations adapted in light of the challenging headwinds our entire industry is facing, we expect H2 2023 trading to stabilize. We are closely monitoring the market and are ready to take further cost reducing action, should we need to. We continue to add value to our high potential key innovation initiatives through focused investment, to position ourselves for when the macro-economic difficulties abate.
I would like to end my statement by thanking our investors, team, advisors and customers for their support during what has been a very challenging period for the company.
Esther Dale-Kolb
Chairwoman
October 26, 2023
For the six months ended June 30, 2023
|
|
|
Six months to |
Six months to |
Year ended |
|
|
|
|
June 30, 2023 |
June 30, 2022 |
December 31, 2022 |
|
|
Note |
|
US$'000 |
US$'000 |
US$'000 |
|
|
|
|
|
(restated*) |
|
|
Revenue |
5 |
|
20,500 |
27,558 |
47,202 |
|
Cost of sales |
7 |
|
(12,110) |
(16,127) |
(33,745) |
|
Gross profit |
|
|
8,390 |
11,431 |
13,457 |
|
Other income |
8 |
|
946 |
2,748 |
4,832 |
|
Selling and general administrative expenses |
9 |
|
(14,263) |
(14,016) |
(30,969) |
|
Impairment loss on intangible assets |
16 |
|
- |
- |
(11,651) |
|
Impairment loss on property, plant & equipment |
17 |
|
- |
- |
(730) |
|
Other expenses |
11 |
|
(1,075) |
(1,735) |
(4,184) |
|
Operating loss |
|
|
(6,002) |
(1,572) |
(29,245) |
|
Finance income |
12 |
|
5 |
442 |
683 |
|
Finance costs |
13 |
|
(384) |
(524) |
(1,273) |
|
Loss before taxation |
|
|
(6,381) |
(1,654) |
(29,835) |
|
Income tax |
14 |
|
(146) |
(254) |
21 |
|
Loss after taxation |
|
|
(6,527) |
(1,908) |
(29,814) |
|
|
|
|
|
|
|
|
Other comprehensive income: |
|
|
|
|
|
|
Exchange differences on translation of foreign operations |
|
|
429 |
(1,090) |
(1,914) |
|
Items that may be reclassified to profit or loss in subsequent periods |
|
|
429 |
(1,090) |
(1,914) |
|
Actuarial gains/(losses) from defined benefit pension plans |
|
|
- |
- |
1,380 |
|
Income tax relating to items that will not be reclassified subsequently to profit or loss |
|
|
- |
- |
(276) |
|
Items that will not be reclassified to profit or loss in subsequent periods |
|
|
- |
- |
1,104 |
|
Other comprehensive income (loss) for the year |
|
|
429 |
(1,090) |
(810) |
|
|
|
|
|
|
|
|
Total comprehensive loss for the year |
|
|
(6,098) |
(2,998) |
(30,624) |
|
|
|
|
|
|
|
|
Loss attributable to: |
|
|
|
|
|
|
Equity holders of HeiQ |
|
|
(6,436) |
(1,705) |
(29,251) |
|
Non-controlling interests |
|
|
(91) |
(203) |
(563) |
|
|
|
|
(6,527) |
(1,908) |
(29,814) |
|
Total Comprehensive loss attributable to: |
|
|
|
|
|
|
Equity holders of the Company |
|
|
(6,007) |
(2,795) |
(30,061) |
|
Non-controlling interests |
|
|
(91) |
(203) |
(563) |
|
|
|
|
(6,098) |
(2,998) |
(30,624) |
|
Loss per share: |
|
|
|
|
|
|
Basic (cents) ** |
|
|
(4.58) |
(1.29) |
(21.92) |
|
*The consolidated statement of profit and loss and other comprehensive income has been restated in the comparative period as described in Note 2.
**The effect of share options is anti-dilutive and therefore not disclosed.
As at June 30, 2023
|
|
As at June 30, 2023 |
As at June 30, 2022 |
As at December 31, 2022 |
|
Note |
US$'000 |
US$'000 |
US$'000 |
|
|
|
(restated*) |
|
ASSETS |
|
|
|
|
Intangible assets |
16 |
21,672 |
32,766 |
20,442 |
Property, plant and equipment |
17 |
8,944 |
6,823 |
9,802 |
Right-of-use assets |
18 |
8,355 |
8,163 |
7,819 |
Deferred tax assets |
28 |
579 |
1,510 |
538 |
Other non-current assets |
19 |
182 |
153 |
137 |
Non-current assets |
|
39,732 |
49,415 |
38,738 |
Inventories |
20 |
14,406 |
16,184 |
13,168 |
Trade receivables |
21 |
8,256 |
18,118 |
6,487 |
Other receivables and prepayments |
22 |
4,231 |
2,022 |
4,262 |
Cash and cash equivalents |
|
7,274 |
9,488 |
8,488 |
Current assets |
|
34,167 |
45,812 |
32,405 |
Total assets |
|
73,899 |
95,227 |
71,143 |
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
Issued share capital and share premium |
24 |
206,246 |
200,606 |
205,874 |
Other reserves |
26 |
(127,456) |
(127,862) |
(128,017) |
Retained deficit |
|
(45,902) |
(10,775) |
(39,466) |
Equity attributable to HeiQ shareholders |
|
32,888 |
61,969 |
38,391 |
Non-controlling interests |
|
1,857 |
2,087 |
1,948 |
Total equity |
|
34,745 |
64,056 |
40,339 |
Lease liabilities |
|
7,089 |
7,148 |
6,558 |
Long-term borrowings |
27 |
1,866 |
1,561 |
1,445 |
Deferred tax liability |
28 |
1,337 |
2,144 |
1,253 |
Other non-current liabilities |
29 |
5,772 |
7,593 |
4,714 |
Total non-current liabilities |
|
16,064 |
18,446 |
13,970 |
Trade and other payables |
30 |
8,653 |
6,959 |
5,322 |
Accrued liabilities |
31 |
3,692 |
2,178 |
4,978 |
Income tax liability |
14 |
243 |
111 |
314 |
Deferred revenue |
32 |
1,365 |
672 |
1,285 |
Short-term borrowings |
27 |
7,471 |
1,583 |
2,893 |
Lease liabilities |
|
1,121 |
1,130 |
1,264 |
Other current liabilities |
34 |
545 |
92 |
778 |
Total current liabilities |
|
23,090 |
12,725 |
16,834 |
Total liabilities |
|
39,154 |
31,171 |
30,804 |
Total equity and liabilities |
|
73,899 |
95,227 |
71,143 |
*The comparative period of the consolidated statement financial position has been added this year because it was restated as described in Note 2.
The Notes form an integral part of these Condensed Consolidated Financial Statements. The Financial Statements were approved and authorized for issue by the Board of Directors on October 26, 2023 and signed on its behalf by:
Xaver Hangartner
Chief Financial Officer
For the six months ended June 30, 2023
|
|
|
|||||
|
|
Issued share capital and share premium |
Other reserves |
Retained deficit |
Equity attributable to HeiQ shareholders |
Non-controlling interests |
Total equity |
|
Note |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Balance at January 1, 2022 |
|
195,714 |
(127,195) |
(11,525) |
56,994 |
2,541 |
59,535 |
Loss after taxation |
|
- |
- |
(29,251) |
(29,251) |
(563) |
(29,814) |
Other comprehensive (loss)/income |
|
- |
(810) |
- |
(810) |
- |
(810) |
Total comprehensive (loss)/income for the year |
|
- |
(810) |
(29,251) |
(30,061) |
(563) |
(30,624) |
Issuance of shares |
24 |
10,160 |
- |
- |
10,160 |
- |
10,160 |
Share-based payment charges |
26 |
- |
(12) |
- |
(12) |
- |
(12) |
Dividends paid to minority shareholders |
26 |
- |
- |
- |
- |
(243) |
(243) |
Capital contributions from minority shareholders |
|
- |
- |
- |
- |
764 |
764 |
Adjustments arising from change in non-controlling interests |
|
- |
- |
(2,445) |
(2,445) |
(616) |
(3,061) |
Transfer on disposal of non-controlling interest |
|
- |
- |
3,755 |
3,755 |
65 |
3,820 |
Transactions with owners |
|
10,160 |
(12) |
1,310 |
11,458 |
(30) |
11,428 |
Balance at December 31, 2022 |
|
205,874 |
(128,017) |
(39,466) |
38,391 |
1,948 |
40,339 |
|
|
|
|
|
|
|
|
Loss after taxation |
|
- |
- |
(6,436) |
(6,436) |
(91) |
(6,527) |
Other comprehensive (loss)/income |
|
- |
429 |
- |
429 |
- |
429 |
Total comprehensive (loss)/income for the year |
|
- |
429 |
(6,436) |
(6,007) |
(91) |
(6,098) |
Issuance of shares |
24 |
372 |
- |
- |
372 |
- |
372 |
Share-based payment charges |
26 |
- |
132 |
- |
132 |
- |
132 |
Transactions with owners |
|
372 |
132 |
- |
504 |
- |
504 |
Balance at June 30, 2023 |
|
206,246 |
(127,456) |
(45,902) |
32,888 |
1,857 |
34,745 |
For the six months ended June 30, 2023
|
|
Six months to |
Six months to |
Year ended |
|
|
June 30, 2023 |
June 30, 2022 |
December 31, 2022 |
|
Note |
US$'000 |
US$'000 |
US$'000 |
|
|
|
(Restated*) |
|
Cash flows from operating activities |
|
|
|
|
Loss before taxation |
|
(6,381) |
(1,654) |
(29,835) |
Cash flow from operations reconciliation: |
|
|
|
|
Depreciation and amortization |
16-18 |
2,258 |
1,807 |
3,655 |
Impairment expense |
11 |
- |
- |
12,380 |
Net loss on disposal of assets |
|
17 |
3 |
(5) |
Write-off of intangible assets |
11 |
14 |
- |
897 |
Fair value gain on derivative liability |
8 |
(248) |
- |
(371) |
Finance costs |
|
217 |
124 |
273 |
Finance income |
|
(5) |
(1) |
(2) |
Pension expense |
|
43 |
117 |
247 |
Non-cash equity compensation |
25 |
132 |
486 |
138 |
Gain from lease modification |
|
(9) |
(68) |
(68) |
Other costs paid in shares |
24 |
- |
- |
235 |
Currency translation |
|
(594) |
(684) |
(61) |
Working capital adjustments: |
|
|
|
|
(Increase)/decrease in inventories |
37 |
(1,238) |
(2,414) |
602 |
Decrease/(Increase) in trade and other receivables |
37 |
(1,617) |
(1,608) |
7,783 |
(Decrease)/Increase in trade and other payables |
37 |
3,118 |
2,448 |
2,543 |
Cash used in operations |
|
(4,293) |
(1,444) |
(1,589) |
Taxes paid |
14 |
(506) |
(529) |
(870) |
Net cash used in operating activities |
|
(4,799) |
(1,973) |
(2,459) |
Cash flows from investing activities |
|
|
|
|
Consideration for acquisition of businesses |
37 |
- |
(1,587) |
(1,587) |
Cash assumed in asset acquisition |
37 |
2 |
- |
65 |
Purchase of property, plant and equipment |
17 |
(584) |
(1,060) |
(3,418) |
Proceeds from the disposal of property, plant and equipment |
|
815 |
37 |
53 |
Development and acquisition of intangible assets |
16 |
(665) |
(1,946) |
(3,865) |
Interest received |
|
5 |
1 |
2 |
Net cash used in investing activities |
|
(427) |
(4,555) |
(8,750) |
Cash flows from financing activities |
|
|
|
|
Interest paid on borrowings |
|
(122) |
(42) |
(110) |
Repayment of leases |
|
(614) |
(452) |
(992) |
Interest paid on leases |
|
(95) |
(82) |
(163) |
Proceeds from disposals of minority interests |
|
- |
2,459 |
4,792 |
Proceeds from borrowings |
27 |
4,998 |
823 |
3,465 |
Repayment of borrowings |
27 |
(265) |
(197) |
(904) |
Dividends paid to minority shareholders |
26 |
- |
(243) |
(243) |
Net cash from financing activities |
|
3,902 |
2,266 |
5,845 |
Net decrease in cash and cash equivalents |
|
(1,324) |
(4,262) |
(5,364) |
Cash and cash equivalents - beginning of the year |
|
8,488 |
14,560 |
14,560 |
Effects of exchange rate changes on the balance of cash held in foreign currencies |
|
110 |
(810) |
(708) |
Cash and cash equivalents - end of the year |
|
7,274 |
9,488 |
8,488 |
* The consolidated statement of cash flows has been restated for the comparative period as described in Note 2.
HeiQ Plc (the Company) is a company limited by shares incorporated and registered in the United Kingdom. Its ultimate controlling party is HeiQ Plc. The address of the Company's registered office is 5th Floor, 15 Whitehall, London, SW1A 2DD.
These financial statements are presented in United States Dollars (US$) which is the presentation currency of the Group, and all values are rounded to the nearest thousand dollars except where otherwise indicated.
The unaudited condensed consolidated interim financial statements have been prepared in accordance with the Disclosure and Transparency Rules of the Financial Conduct Authority and International Accounting Standard 34 "Interim Financial Reporting" (IAS 34). Other than as noted below, the accounting policies applied by the Group in the preparation of these interim financial statements are the same as those set out in the Company's audited financial statements for the year ended December 31, 2022. These financial statements have been prepared under the historical cost convention except for certain financial and equity instruments that have been measured at fair value.
These condensed financial statements do not include all of the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the audited financial statements for the year ended December 31, 2022.
Statutory accounts for the year ended December 31, 2022 have been filed with the Registrar of Companies in October 2023 and the auditor's report was unqualified, did not contain any statement under Section 498(2) or 498(3) of the Companies Act 2006, and contained a matter (material uncertainty in regards to the going concern assumption) to which the auditors drew attention without qualifying their report.
The condensed interim financial statements are unaudited and have not been reviewed by the auditors and were approved by the Board of Directors on October 26, 2023.
The unaudited condensed consolidated interim financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realization of the assets and the settlement of liabilities in the normal course of business.
To manage its cash balance, the Group has access to credit facilities totalling CHF9.0 million (approximately US$9.8 million as of September 30, 2023). The credit facilities are in place with two different banks but with materially the same conditions. The facilities are not limited in time, can be terminated by either party at any time and allow overdrafts and fixed cash advances with a duration of up to twelve months. In case one or the other party terminates the agreement, fixed cash advances become due upon their defined maturity date. The facilities do not contain financial covenants, but they do require the delivery of certain financial and operational information within a defined timeframe after the balance sheet date. As the publication of audited accounts for the year 2022 was delayed, the Company was not able to submit these accounts within the contractually defined timeframe but has received extensions to do so from both banks until October 31, 2023.
As of September 30, 2023, the Group has drawn CHF6.3 million of the facilities (CHF2.4 million as December 31, 2022) as follows:
Term / Maturity date |
CHF |
November 27, 2023 |
4.5 million |
June 17, 2024 |
0.8 million |
September 30, 2024 |
1.0 million |
The Group's forecasts and projections for the next 12 months reflect the very challenging trading environment and show that the Group should be able to operate within the level of its current facility for at least 12 months from the date of signature of these financial statements if the facility drawdowns remain available. While the facilities are not committed, the Board has not received any indication from financing partners that the facilities are at risk of being terminated. Furthermore, the Board is in discussions with financial institutions to replace the currently uncommitted credit facilities by committed, long-term facilities, but the outcome of these discussions remains uncertain.
Nevertheless, the Board acknowledges the uncommitted status of the facilities which could be terminated without notice during the forecast period requiring the refinancing of debts as per above maturity date indicates that a material uncertainty exists that may cast significant doubt on the Group's and Parent Company's ability to continue as a going concern, and therefore the Group may not be able to realize its assets and discharge its liabilities in the normal course of business.
After considering the forecasts, sensitivities, and mitigating actions available to management and having regard to the risks and uncertainties to which the Group is exposed (including the material uncertainty referred to above), the Group's directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future and operate within its credit facilities for the period 12 months from date of signature. Accordingly, the financial statements continue to be prepared on a going concern basis.
The Condensed Consolidated Financial Statements comprise the financial statements of the Company and its subsidiaries. Business combinations are accounted for under the acquisition method.
As explained in Note 2 of the 2022 statutory accounts, several errors were corrected which affected the years ended December 31 2022 and December 31 2021. These corrections led to the following restatements of the June 30, 2022 accounts:
Overstatement of lease assets and liabilities: Similarly to the correction as per December 31, 2021, mainly balance sheet accounts were affected by the restatement. Right-of-use assets and lease liabilities were derecognized, and some payables were reclassified to loans.
PPA Chrisal: Accounting for 51% of intangible assets acquired instead of 100%: The correction of the error led to an increase in intangible assets as disclosed in the restated 2021 accounts, however, with the higher base amount amortization for the six months ended June 30, 2022 is also higher for the period which is reflected in an overall smaller adjustment to the balance sheet.
Correcting revenue recognition of take-or-pay contracts: The correction of the revenue recognition in years prior to 2022, led to smaller balances of trade receivable and accrued liabilities being carried forward to the June 2022 accounts.
Goodwill impairment Chrisal CGU and RAS CGU: The intangible asset balance brought forward to June 2022 has been reduced by the goodwill impairment posted in the 2021 accounts.
Correcting revenue recognition of R&D services: Revenues amounting to $2 million for R&D services were incorrectly recognized in the 2022 interim statements. During the audit of 2022 financial statements, it was found that the Group's performance obligations relating to a research and development project had not been fulfilled and that revenue recognition in relation to milestones was not appropriate. A further US$3.3 million of deferred revenue has been reclassified to long-term as a consequence of this change in accounting policy.
The effect of the restatements on the six months ended June 30, 2022 is shown in the following tables:
Consolidated statement of financial position
June 30, 2022
US$'000 |
As presented |
Restatement Revenue recognition |
Restatement Goodwill impairment |
Restatement Leasing |
Restatement PPA Chrisal |
Restatement R&D revenues |
As Restated |
Assets |
|
|
|
|
|
|
|
Intangible assets |
33,448 |
- |
(2,310) |
- |
1,628 |
- |
32,766 |
Right-of-use assets |
9,114 |
- |
- |
(951) |
- |
- |
8,163 |
Deferred tax assets |
874 |
- |
- |
- |
- |
- |
1,510 |
Trade receivables |
21,512 |
(3,394) |
- |
- |
- |
- |
18,118 |
Other receivables and prepayments |
5,143 |
(3,121) |
- |
- |
- |
- |
2,022 |
Total Assets |
102,739 |
(5,879) |
(2,310) |
(951) |
1,628 |
- |
95,227 |
|
|
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
|
|
|
Retained deficit |
(2,249) |
(3,957) |
(2,310) |
3 |
(262) |
(2,000) |
10,775 (10,775) |
Non-controlling interests |
601 |
- |
- |
3 |
1,483 |
- |
2,087 |
Total Equity |
71,096 |
(3,957) |
(2,310) |
6 |
1,221 |
(2,000) |
64,056 |
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Leases (non-current) |
7,977 |
- |
- |
(829) |
- |
- |
7,148 |
Long-term borrowings |
668 |
- |
- |
893 |
- |
- |
1,561 |
Deferred tax liability |
1,737 |
- |
- |
- |
407 |
- |
2,144 |
Other non-current liabilities |
2,293 |
- |
- |
- |
- |
5,300 |
7,593 |
Trade and other payables |
7,928 |
- |
- |
(969) |
- |
- |
6,959 |
Accrued liabilities |
4,100 |
(1,922) |
- |
- |
- |
- |
2,178 |
Deferred revenue |
3,972 |
- |
- |
- |
- |
(3,300) |
672 |
Short-term borrowings |
1,503 |
- |
- |
80 |
- |
- |
1,583 |
Leases (current) |
1,262 |
- |
- |
(132) |
- |
- |
1,130 |
Total Liabilities |
31,643 |
(1,922) |
- |
(957) |
407 |
- |
31,171 |
Consolidated statement of comprehensive income
June 30, 2022
US$'000 |
As presented |
Restatement Revenue recognition |
Restatement Goodwill impairment |
Restatement Leasing |
Restatement PPA Chrisal |
Restatement R&D revenues |
As Restated |
Net result for the period |
|
|
|
|
|
|
|
Revenue |
30,280 |
(722) |
- |
- |
- |
(2,000) |
(27,558) |
Selling and general administration expense |
(13,878) |
- |
- |
(7) |
(131) |
- |
(14,016) |
Finance costs |
(537) |
- |
- |
13 |
- |
- |
(524) |
Income tax |
(287) |
- |
- |
- |
33 |
- |
(254) |
Income (loss) after taxation |
906 |
(722) |
- |
6 |
(98) |
(2,000) |
(1,654)) |
Income (loss) after taxation attributable to HeiQ Stockholders |
1,112 |
(722) |
- |
3 |
(98) |
(2,000) |
(1,705) |
Income after taxation attributable to non-controlling interest |
(206) |
- |
- |
3 |
- |
- |
(203) |
Income (loss) after taxation |
906 |
(722) |
- |
6 |
(98) |
(2,000) |
(1,908) |
Earnings per share
June 30, 2022
US$'000 |
As presented |
Restatement Revenue recognition |
Restatement Goodwill impairment |
Restatement Leasing |
Restatement PPA Chrisal |
Restatement R&D revenues |
As Restated |
Basic earnings (loss) per share |
0.84 |
(0.55) |
- |
- |
(0.07) |
(1.51) |
(1.29) |
The following new standards and amendments were effective for the first time in these financial statements but did not have a material effect on the Group:
• Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2);
• Classification of Liabilities as Current or Non-current (Amendments to IAS 1);
• Definition of Accounting Estimates (Amendments to IAS 8); and
• Deferred Tax Related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12).
The Company has applied the same accounting policies and methods of computation in its interim consolidated financial statements as in its 2022 financial statements.
New and amended standards and Interpretations issued by the IASB that will apply for the first time in the next annual financial statements are not expected to impact the Group as they are either not relevant to the Group's activities or require accounting which is consistent with the Group's current accounting policies.
There have been no material revisions to the nature and amounts of estimates of amounts reported in prior periods.
On January 12, 2023, HeiQ Plc, completed the acquisition of the entire issued share capital of Tarn-Pure Holdings Ltd ("Tarn-Pure"). Tarn-Pure is a UK-based intellectual property company holding critical EU and UK regulatory registrations to sell elemental copper and elemental silver for use in disinfecting hygiene applications. To acquire Tarn-Pure, HeiQ paid the vendors £530,000 (approximately US$621,000) in cash with an additional £317,000 (approximately US$372,000) satisfied through the issuance of 455,435 new ordinary shares of 30p each in the Company (the "Consideration Shares"), issued at a price of 69.6p per share resulting in a total consideration of £847,000 (approximately US$993,000). The purchase price allocation has not been finalized yet and is subject to possible changes in valuation of the assets acquired. it will be completed in the 2023 annual report.
The following table provides an overview of the preliminary purchase price allocation. It summarizes the consideration paid, the fair value of assets acquired, liabilities assumed, and goodwill arising on acquisition at the acquisition date.
Preliminary purchase price allocation |
US$'000 |
Consideration: |
|
Cash paid to shareholders |
621 |
Shares issued to shareholders |
372 |
Total Consideration |
993 |
|
|
Fair value of net assets acquired: |
|
Inventory |
13 |
Cash |
2 |
Trade and other receivables |
23 |
Borrowings |
(42) |
Intangible assets identified on acquisition: |
|
Customer Relationship |
123 |
Regulatory asset |
682 |
Deferred tax liability on intangible assets |
(201) |
Total net assets |
599 |
Goodwill |
394 |
Total |
993 |
The Group's focus on materials innovation which includes scientific research, manufacturing and consumer ingredient branding. The primary source of revenue is the production and sale of functional ingredients, materials and finished goods. Other sources of revenue include research and development, take-or-pay and exclusivity services.
The following table reconciles HeiQ Group's revenue for the periods presented:
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Revenue by type of product |
US$'000 |
US$'000 |
US$'000 |
Revenue recognized at point in time |
|
|
|
Functional ingredients |
15,747 |
21,156 |
36,175 |
Functional materials |
546 |
434 |
2,000 |
Functional consumer goods |
2,702 |
5,042 |
6,827 |
Services |
980 |
160 |
160 |
Revenue recognized over time |
|
|
|
Services |
525 |
766 |
2,040 |
Total revenue |
20,500 |
27,558 |
47,202 |
The transaction prices allocated to unsatisfied and partially unsatisfied obligations at June 30, 2023 are as set out below:
|
|
|
As at June 30, 2023 |
As at December 31, 2022 |
Unsatisfied performance obligations |
|
|
US$'000 |
US$'000 |
Exclusivity services |
|
|
1,800 |
2,100 |
Research and development services |
|
|
3,500 |
3,750 |
Total unsatisfied performance obligations |
|
|
5,300 |
5,850 |
Management expects that 10 per cent of the transaction price allocated to the unsatisfied contracts as of June 2023 will be recognized as revenue during the 2023 reporting period (US$0.5 million). The remaining 90 per cent, US$4.8 million will be recognized in the 2024 (US$1.1 million), 2025 (US$3.1 million) and 2026 financial year (US$0.6 million).
Contract assets and contract liabilities are disclosed under Note 23 and Note 33, respectively. Impairment losses recognized on any receivables or contract assets arising from the Group's contracts with customers are disclosed under Note 21 and Note 23, respectively.
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors of the Company.
For management purposes, the Group is organised into business units and the following reportable segments:
Segment |
Activity |
Textiles & Flooring |
Provide innovative ingredients to make textiles & flooring more functional, durable and sustainable. |
Life Sciences |
Offer biotech solutions to replace harmful substances in domestic, commercial and industrial usage, for a more balanced microbiome and environment |
Antimicrobials |
Functionalize different hard surfaces in everyday products and our surroundings |
Other activities |
All other activities of the Group including Innovation Services, Business Development, and other non-allocated functions. |
In 2023 new overhead allocation rules were introduced and as a result more overhead costs were allocated to segments. 2022 segment revenue and profits are restated below using the new rules to allow for like for like comparison.
The following is an analysis of the Group's revenue and results by reportable segment:
|
|
|
|
|
|
Six months to June 30, 2023 |
Textiles & Flooring |
Life Sciences |
Antimicrobials |
Other activities |
Total |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Revenue |
15,531 |
2,479 |
1,164 |
1,326 |
20,500 |
Operating profit (loss) |
1,117 |
(693) |
(1,710) |
(4,716) |
(6,002) |
Finance result |
|
|
|
|
(379) |
Loss before taxation |
|
|
|
|
(6,381) |
Taxation |
|
|
|
|
(146) |
Loss after taxation |
|
|
|
|
(6,527) |
Depreciation and amortization |
|
|
|
|
|
Property, plant and equipment |
298 |
171 |
15 |
227 |
710 |
Right-of use assets |
90 |
74 |
22 |
292 |
479 |
Intangible assets |
144 (144) |
277 |
401 |
247 |
1,069 |
Impairment loss |
|
|
|
|
|
Property, plant and equipment |
- |
- |
- |
- |
- |
Intangible assets |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
|
|
|
|
|
Six months to June 30, 2022 |
Textiles & Flooring |
Life Sciences |
Antimicrobials |
Other activities |
Total |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Revenue |
19,538 |
3,891 |
3,028 |
1,102 |
27,558 |
Operating profit (loss) |
2,682 |
(537) |
(468) |
(3,249) |
(1,572) |
Finance result |
|
|
|
|
(82) |
Loss before taxation |
|
|
|
|
(1,654) |
Taxation |
|
|
|
|
(254) |
Loss after taxation |
|
|
|
|
(1,908) |
Depreciation and amortization |
|
|
|
|
|
Property, plant and equipment |
208 |
173 |
17 |
246 |
644 |
Right-of use assets |
75 |
72 |
24 |
325 |
497 |
Intangible assets |
36 |
274 |
349 |
7 |
666 |
Impairment loss |
|
|
|
|
|
Property, plant and equipment |
- |
- |
- |
- |
- |
Intangible assets |
- |
- |
- |
- |
- |
Year ended December 31, 2022 |
Textiles & Flooring |
Life Sciences |
Antimicrobials |
Other activities |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Total |
|
Revenue |
34,184 |
6,164 |
4,182 |
2,672 |
47,202 |
Operating profits loss |
(4,231) |
(5,537) |
(10,116) |
(9,359) |
(29,245) |
Finance result |
|
|
|
|
(590) |
Loss before taxation |
|
|
|
|
(29,835) |
Taxation |
|
|
|
|
21 |
Loss after taxation |
|
|
|
|
(29,814) |
Depreciation and amortization |
|
|
|
|
|
Property, plant and equipment |
334 |
335 |
28 |
585 |
1,282 |
Right-of use assets |
123 |
145 |
42 |
628 |
938 |
Intangible assets |
(107) |
550 |
699 |
293 |
1,435 |
Impairment loss |
|
|
|
|
|
Property, plant and equipment |
- |
730 |
- |
- |
730 |
Intangible assets |
- |
2,402 |
8,247 |
1,002 |
11,651 |
Segment revenue reported above represents revenue generated from external customers. There were no intersegment sales in the six months ended June 30, 2023 (2022: nil).
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Revenue by region |
|
US$'000 |
US$'000 |
US$'000 |
North & South America |
|
9,694
|
11,098 |
20,425 |
Asia |
|
4,798 |
8,955 |
13,376 |
Europe |
|
5,848 |
7,327 |
13,109 |
Others |
|
160 |
178 |
293 |
Total revenue |
|
20,500 |
27,558 |
47,202 |
|
|
As at |
As at December 31, |
|
|
June 30, 2023 |
2022 |
Non-current assets by region |
|
US$'000 |
US$'000 |
Europe |
|
28,956 |
22,290 |
Asia |
|
2,701 |
8,102 |
North & South America |
|
7,557 |
7,734 |
Others |
|
518 |
612 |
Total non-current assets |
|
39,732 |
38,738 |
During the six months ended June 30, 2023, no customers individually totalled more than 10% of total revenues (2022: none).
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Cost of sales |
|
US$'000 |
US$'000 |
US$'000 |
Material expenses |
|
10,351 |
12,114 |
20,942 |
Personnel expenses |
|
1,563 |
1,477 |
2,830 |
Depreciation of property, plant and equipment |
|
352 |
342 |
652 |
Other costs of sales |
|
(156) |
2,194 |
9,321 |
Total cost of sales |
|
12,110 |
16,127 |
33,745 |
Other costs of goods sold include freight and custom costs, warehousing and allowances on inventory.
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Other income |
|
US$'000 |
US$'000 |
US$'000 |
Gain on disposal of property plant and equipment |
|
12 |
9 |
21 |
Foreign exchange gains |
|
517 |
2,334 |
3,539 |
Fair value gain on derivative liabilities |
|
248 |
- |
371 |
Other income |
|
169 |
405 |
901 |
Total other income |
|
946 |
2,748 |
4,832 |
Selling and general administration expenses |
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
|
US$'000 |
US$'000 |
US$'000 |
|
|
|
(restated*) |
|
|
Personnel expenses |
|
6,849 |
7,808 |
14,977 |
Depreciation of property, plant and equipment |
|
358 |
302 |
630 |
Amortization |
|
1,069 |
666 |
1,435 |
Depreciation of right-of-use assets |
|
479 |
497 |
938 |
Net credit losses on financial assets and contract assets |
|
- |
- |
85 |
Other |
|
5,508 |
4,743 |
12,904 |
Total selling and general administration expenses |
|
14,263 |
14,016 |
30,969 |
Other selling and general administration expenses include costs for infrastructure, professional services and marketing as well as R&D and laboratory related costs, information technology & data expenses, sales representative & distribution expenses.
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Personnel expenses |
|
US$'000 |
US$'000 |
US$'000 |
Wages & salaries |
|
7,224 |
7,930 |
15,274 |
Social security & other payroll taxes |
|
802 |
624 |
1,685 |
Pension costs |
|
254 |
244 |
710 |
Share-based payments |
|
132 |
486 |
138 |
Total personnel expenses |
|
8,412 |
9,285 |
17,807 |
Reported as cost of sales (Note 7) |
|
1,563 |
1,477 |
2,830 |
Reported as selling and general administration expense (Note 9) |
|
6,849 |
7,808 |
14,977 |
Total personnel expenses |
|
8,412 |
9,285 |
17,807 |
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Other expenses |
|
US$'000 |
US$'000 |
US$'000 |
Foreign exchange losses |
|
928 |
1,621 |
3,050 |
Loss on disposal of property, plant and equipment |
|
30 |
12 |
16 |
Transaction costs relating to mergers and acquisitions |
|
23 |
- |
50 |
Write off intangible assets |
|
14 |
- |
897 |
Other |
|
80 |
102 |
171 |
Total other expenses |
|
1,075 |
1,735 |
4,184 |
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Finance income |
|
US$'000 |
US$'000 |
US$'000 |
Interest income |
|
3 |
1 |
5 |
Gains on foreign currency transactions |
|
- |
440 |
678 |
Other |
|
2 |
1 |
- |
Total finance income |
|
5 |
442 |
683 |
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Finance costs |
|
US$'000 |
US$'000 |
US$'000 |
|
|
(restated*) |
|
|
Lease finance expense |
|
95 |
81 |
163 |
Interest on borrowings |
|
122 |
43 |
110 |
Bank fees |
|
167 |
34 |
98 |
Loss on foreign currency transactions |
|
- |
366 |
902 |
Total finance costs |
|
384 |
524 |
1,273 |
The components of the provision for taxation on income included in the "Statement of profit or loss and other comprehensive income" are summarized below:
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022 |
Year ended December 31, 2022 |
Current income tax expense |
|
US$'000 |
US$'000 |
US$'000 |
Swiss corporate income taxes |
|
21 |
30 |
58 |
United States state and federal taxes |
|
101 |
383 |
393 |
Taiwan corporate income taxes |
|
81 |
78 |
118 |
Belgium corporate income taxes |
|
83 |
76 |
(123) |
Germany corporate income taxes |
|
- |
(17) |
51 |
Others |
|
11 |
79 |
63 |
Total current income tax expense |
|
297 |
629 |
560 |
Deferred income tax expense |
|
|
|
|
|
|
(restated*) |
|
|
Switzerland |
|
(22) |
(69) |
90 |
United States |
|
(4) |
(71) |
(606) |
China |
|
(2) |
(128) |
117 |
Austria |
|
(2) |
(4) |
20 |
Belgium |
|
(68) |
(71) |
(136) |
Others |
|
(53) |
(32) |
(66) |
Total deferred income tax expense (income) |
|
(151) |
(375) |
(581) |
|
|
|
|
|
Total income tax expense (income) |
|
(146) |
(254) |
(21) |
|
|
As at June 30, |
As at December 31, |
|
|
2023 |
2022 |
Net tax (assets)/liabilities |
|
US$'000 |
US$'000 |
Opening balance - (prepaid taxes) |
|
(343) |
51 |
Assumed on asset acquisition |
|
- |
(32) |
Income tax expense for the year |
|
297 |
560 |
Taxes paid |
|
(506) |
(870) |
Foreign currency differences |
|
(3) |
(52) |
Net tax (asset)/liability |
|
(555) |
(343) |
|
|
As at |
As at |
|
|
June 30, |
December 31, |
|
|
2023 |
2022 |
Net tax (assets) liabilities |
|
US$'000 |
US$'000 |
Prepaid income taxes |
|
(798) |
(657) |
Income tax liabilities |
|
243 |
314 |
Net tax (asset)/liability |
|
(555) |
(343) |
The calculation of the basic earnings per share is based on the following data:
|
|
Six months to June 30, 2023 |
Six months to June 30, 2022* |
Year ended December 31, 2022 |
Earnings |
|
US$'000 |
US$'000 |
US$'000 |
Loss attributable to the ordinary equity holders of the parent entity |
|
(6,436) |
(1,705) |
(29,251) |
*Earnings have been restated in the comparative period as described in note 2.
The effect of share options is anti-dilutive and therefore not disclosed.
|
|
As at June 30, 2023 |
As at June 30, 2022 |
As at December 31, 2022 |
Number of shares |
|
US$'000 |
US$'000 |
US$'000 |
Weighted average number of ordinary shares for the purposes of basic earnings per share |
|
140,507,712 |
131,781,726 |
133,426,953 |
Basic earnings per share is calculated by dividing the profit/loss after tax attributable to the equity holders of the Company by the weighted average number of shares in issue during the year. The effect of share options is anti-dilutive and therefore not disclosed.
|
Goodwill |
Internally developed assets |
Brand names and customer relations |
Acquired technologies |
Other intangible assets |
Total |
Cost |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
As at January 1, 2022 |
21,382 |
3,509 |
4,503 |
3,180 |
2,332 |
34,906 |
Additions arising from internal development |
- |
2,165 |
- |
- |
- |
2,165 |
Other acquisitions |
- |
- |
- |
- |
1,700 |
1,700 |
Disposals / write-offs |
- |
(85) |
- |
- |
(812) |
(897) |
Currency translation differences |
(795) |
5 |
(160) |
(165) |
14 |
(1,101) |
As at December 31, 2022 |
20,587 |
5,594 |
4,343 |
3,015 |
3,234 |
36,773 |
Additions arising from internal development |
-
|
583 |
- |
- |
- |
583 |
Business combinations |
394 |
- |
123 |
- |
682 |
1,199 |
Other acquisitions |
- |
- |
- |
- |
82 |
82 |
Disposals / write-offs |
- |
(14) |
- |
- |
- |
(14) |
Currency translation differences |
294 |
162 |
61 |
57 |
73 |
647 |
As at June 30, 2023 |
21,275 |
6,325 |
4,527 |
3,072 |
4,071 |
39,270 |
Amortization and accumulated impairment losses |
|
|
|
|||
As at January 1, 2022 |
2,305 |
474 |
602 |
234 |
518 |
4,133 |
Amortization for the period |
- |
198 |
695 |
334 |
208 |
1,435 |
Impairment loss |
10,576 |
880 |
73 |
- |
122 |
11,651 |
Currency translation differences |
(750) |
3 |
(72) |
(45) |
(24) |
(888) |
As at December 31, 2022 |
12,131 |
1,555 |
1,298 |
523 |
824 |
16,331 |
Amortization for the period |
- |
331 |
360 |
167 |
211 |
1,069 |
Currency translation differences |
158 |
48 |
(5) |
(3) |
- |
198 |
As at June 30, 2023 |
12,289 |
1,934 |
1,653 |
687 |
1,035 |
17,598 |
Net book value |
|
|
|
|
|
|
As at December 31, 2022 |
8,456 |
4,039 |
3,045 |
2,492 |
2,410 |
20,442 |
As at June 30, 2023 |
8,986 |
4,391 |
2,874 |
2,385 |
3,036 |
21,672 |
|
Machinery and equipment |
Motor vehicles |
Computers and software |
Furniture and fixtures |
Land and buildings |
Total |
Cost |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
As at January 1, 2022 |
7,288 |
536 |
914 |
474 |
1,523 |
10,735 |
Additions |
2,272 |
26 |
197 |
50 |
2,736 |
5,280 |
Disposals |
(69) |
(12) |
- |
- |
- |
(81) |
Reclassifications |
(407) |
59 |
- |
348 |
- |
- |
Currency translation differences |
(233) |
(1) |
(21) |
(23) |
(91) |
(369) |
As at December 31, 2022 |
8,851 |
608 |
1,090 |
849 |
4,168 |
15,565 |
Additions |
504 |
32 |
2 |
42 |
4 |
584 |
Disposals |
(807) |
(45) |
(3) |
- |
- |
(855) |
Reclassifications |
(32) |
- |
- |
32 |
- |
- |
Currency translation differences |
118 |
2 |
29 |
17 |
41 |
207 |
As at June 30, 2023 |
8,634 |
597 |
1,118 |
940 |
4,213 |
15,502 |
Depreciation and accumulated impairment losses |
|
|
|
|
||
As at January 1, 2022 |
2,723 |
330 |
619 |
86 |
112 |
3,870 |
Charge for the year |
763 |
90 |
218 |
83 |
128 |
1,282 |
Eliminated on disposal |
(27) |
(5) |
- |
- |
- |
(32) |
Impairment loss |
730 |
- |
- |
- |
- |
730 |
Reclassifications |
(222) |
- |
- |
222 |
- |
- |
Currency translation differences |
(67) |
- |
(9) |
(3) |
(7) |
(86) |
As at December 31, 2022 |
3,900 |
415 |
828 |
388 |
233 |
5,764 |
Charge for the period |
437 |
42 |
59 |
55 |
117 |
710 |
Eliminated on disposal |
- |
(21) |
(1) |
- |
- |
(22) |
Currency translation differences |
68 |
1 |
24 |
7 |
7 |
106 |
As at June 30, 2023 |
4,405 |
437 |
910 |
450 |
356 |
6,558 |
Net book value |
|
|
|
|
|
|
As at December 31, 2022 |
4,951 |
193 |
262 |
461 |
3,935 |
9,802 |
As at June 30, 2023 |
4,229 |
160 |
208 |
490 |
3,856 |
8,944 |
|
Land and buildings |
Motor vehicles |
Machinery and equipment |
Total |
Cost |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
As at January 1, 2022 |
8,913 |
611 |
341 |
9,865 |
Additions |
86 |
174 |
1,921 |
2,181 |
Disposals due to expiry of lease |
- |
(36) |
- |
(36) |
Disposals due to business combination* |
(467) |
- |
- |
(467) |
Modification to lease terms** |
(1,199) |
- |
- |
(1,199) |
Currency translation differences |
(381) |
(67) |
(26) |
(474) |
As at December 31, 2022 |
6,952 |
682 |
2,236 |
9,870 |
Additions |
98 |
93 |
791 |
982 |
Disposals due to expiry of lease |
(220) |
- |
- |
(220) |
Modification to lease terms** |
(253) |
(54) |
- |
(307) |
Currency translation differences |
160 |
18 |
30 |
208 |
As at June 30, 2023 |
6,737 |
739 |
3,057 |
10,533 |
Depreciation |
|
|
|
|
As at January 1, 2022 |
1,716 |
109 |
66 |
1,891 |
Depreciation for the year |
730 |
140 |
68 |
938 |
Disposals due to expiry of lease |
- |
(36) |
- |
(36) |
Modification to lease terms** |
(693) |
- |
- |
(693) |
Currency translation differences |
(34) |
(6) |
(9) |
(49) |
As at December 31, 2022 |
1,719 |
207 |
125 |
2,051 |
Depreciation for the period |
357 |
76 |
46 |
479 |
Disposals due to expiry of lease |
(118) |
- |
(32) |
(150) |
Modification to lease terms** |
(173) |
(16) |
- |
(189) |
Currency translation differences |
(21) |
5 |
3 |
(13) |
As at June 30, 2023 |
1,764 |
272 |
142 |
2,178 |
Net book value |
|
|
|
|
As at December 31, 2022 |
5,233 |
475 |
2,111 |
7,819 |
As at June 30, 2023 |
4,973 |
467 |
2,915 |
8,355 |
*With the acquisition of ChemTex Laboratories' property, plant and equipment, the Group no longer has a lease liability with a third party.
**The Group agreed to shorten the agreed lease terms of two existing leases from 2032 to 2027. These modifications have resulted in a reduction in the total amounts payable under the leases and a reduction to both of the right-of-use assets and lease liabilities with effect from the date of modification.
|
|
As at |
|
As at |
|
|
June 30, 2023 |
|
December 31, 2022 |
Other non-current assets |
|
US$'000 |
|
US$'000 |
Deposits |
|
96 |
|
80 |
Other prepayments |
|
86 |
|
57 |
Other non-current assets |
|
182 |
|
137 |
|
|
As at |
|
As at |
|
|
June 30, 2023 |
|
December 31, 2022 |
Inventories |
|
US$'000 |
|
US$'000 |
Functional ingredients |
|
11,044 |
|
7,420 |
Functional materials |
|
1,188 |
|
4,000 |
Functional consumer goods |
|
2,174 |
|
1,748 |
Total inventories |
|
14,406 |
|
13,168 |
The cost of inventories recognized as an expense in the six months ended June 30, 2023 in respect of continuing operations was US$12,110,000 (December 31, 2022: US$33,597,000).
|
|
As at |
As at |
|
|
June 30, 2023 |
December 31, 2022 |
Trade receivables |
|
US$'000 |
US$'000 |
Not past due |
|
5,027 |
2,788 |
< 30 days |
|
1,256 |
520 |
31-60 days |
|
402 |
781 |
61-90 days |
|
667 |
215 |
91-120 days |
|
94 |
180 |
>120 days |
|
1,223 |
2,407 |
Total trade receivables |
|
8,669 |
6,891 |
Provision for expected credit losses |
|
(413) |
(404) |
Total trade receivables (net) |
|
8,256 |
6,487 |
The average credit period on sales of goods varies by region from 30 - 120 days. No interest is charged on outstanding trade receivables. The Group always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtor and an analysis of the debtor's current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as the forecast.
As at June 30, 2023, the Group has recognized an expected credit loss of US$413,000 (2021: US$404,000).
|
|
As at |
|
As at |
|
|
June 30, 2023 |
|
December 31, 2022 |
Total other receivables and prepayments |
US$'000 |
|
US$'000 |
|
Contract assets |
|
108 |
|
115 |
Receivables from tax authorities |
|
2,271 |
|
1,864 |
Prepayments |
|
969 |
|
1,023 |
Other receivables |
|
883 |
|
1,260 |
Total other receivables and prepayments |
|
4,231 |
|
4,262 |
Amounts relating to contract assets are balances due from customers under construction contracts that arise when the Group receives payments from customers in line with a series of performance-related milestones. The Group recognizes a contract asset for any work performed. Any amount previously recognized as a contract asset is reclassified to trade receivables at the point at which it is invoiced to the customer.
|
As at June 30, 2023 |
As at December 31, 2022 |
Contract assets |
US$'000 |
US$'000 |
Research and development services |
108 |
65 |
Exclusivity services |
- |
50 |
Total contract assets |
108 |
115 |
Current assets |
108 |
115 |
Non-current assets |
- |
- |
Total contract assets |
108 |
115 |
Revenues related to research and development services were recognized at the point of delivering proof of concept and completing testing services. Performance obligations related to exclusivity services were deemed fulfilled by the Group upon completion of the contractual term. Payment for the above services is not due from the customer yet and therefore a contract asset is recognized.
The directors of the Company always measure the loss allowance on amounts due from customers at an amount equal to lifetime ECL, taking into account the historical default experience, the nature of the customer and where relevant, the sector in which they operate. There has been no change in the estimation techniques or significant assumptions made during the current reporting period in assessing the loss allowance for the amounts due from customers under construction contracts.
The following table details the risk profile of amounts due from customers based on the Group's provision matrix. Based on the historic default experience, the following expected credit loss has been recognized:
|
As at June 30, 2023 |
As at December 31, 2022 |
Expected credit loss |
US$'000 |
US$'000 |
Expected credit loss rate |
0% |
0% |
Estimated total gross carrying amount at default |
108 |
115 |
Lifetime ECL |
- |
- |
Net carrying amount |
108 |
115 |
Movements in the Company's share capital and share premium account were as follows:
|
|
Number of shares |
Share capital |
Share premium |
Totals |
|
|
No. |
US$'000 |
US$'000 |
US$'000 |
Balance as of January 1, 2022 |
|
130,583,536 |
51,523 |
144,191 |
195,714 |
Issue of shares to vendors of Life Materials |
|
347,552 |
141 |
471 |
612 |
Issue of shares as deferred consideration |
|
3,461,615 |
1,359 |
2,921 |
4,280 |
Issue of shares to Advisory Board and others |
|
164,721 |
60 |
175 |
235 |
Issue of shares to vendors of ChemTex Labs |
|
2,176,884 |
795 |
1,177 |
1,972 |
Issue of shares to vendors of Chrisal |
|
3,348,164 |
1,223 |
1,838 |
3,061 |
Balance as at December 31, 2022 |
|
140,082,472 |
55,101 |
150,773 |
205,874 |
Issue of shares Tarn Pure (a) |
|
455,435 |
160 |
212 |
372 |
Balance as at June 30, 2023 |
|
140,537,907 |
55,261 |
150,985 |
206,246 |
The par value of all shares is £0.30. All shares in issue were allotted, called up and fully paid.
The share premium account represents the amount received on the issue of ordinary shares by the Company in excess of their nominal value and is non-distributable.
The Company issued new ordinary shares for the following:
On January 12, 2023, HeiQ plc completed the acquisition of 100% of the issued share capital and voting rights of Tarn Pure for a total consideration of US$993,000. The purchase consideration was payable partly in cash (US$621,000) and partly by the issue of 455,435 new ordinary shares for (US$372,000). See Note 4 for details.
Following employee departures, the number of options expected to vest dropped to 2,279,236 as per June 30, 2023 (December 31, 2022: 2,497,281). The expense arising from these share-based payment transactions was US$132,000 for the six months ended June 30, 2023 which compares against an income of US$12,000 for the year ended December 31, 2022 following a drop in market expectations during the second half of 2022. In the six months ended June 30, 2022, the Group incurred an expense of US$415,000.
Remuneration of US$764,000 in relation to the acquisition of Life Materials Technologies Limited is linked to a service period of five years. An expense of US$75,000 was recognized in the six months ended June 30, 2023 (six months ended June 30, 2023: US$71,000; year ended December 31, 2022: US$150,000). The remainder of approximately US$469,000 is expected to be expensed over the period from July 1, 2023, to June 30, 2026.
Other reserves comprise the share-based payment reserve, the merger reserve, the currency translation reserve and the other reserve.
The retained deficit comprises all other net gains and losses and transactions with owners not recognized elsewhere.
Movements in the other reserves were as follows:
|
|
Share- based payment reserve |
Merger reserve |
Currency translation reserve |
Other reserve |
Total Other reserves |
|
|
Note |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Balance at January 1, 2022 |
|
474 |
(126,912) |
387 |
(1,144) |
(127,195) |
|
Other comprehensive (loss)/income |
|
- |
- |
(1,914) |
1,104 |
(810) |
|
Total comprehensive (loss)/income for the year |
|
- |
- |
(1,914) |
1,104 |
(810) |
|
Share-based payment charges |
25 |
(12) |
- |
- |
- |
(12) |
|
Transactions with owners |
|
(12) |
- |
- |
- |
(12) |
|
Balance at December 31, 2022 |
|
462 |
(126,912) |
(1,527) |
(40) |
(128,017) |
|
Other comprehensive (loss)/income |
|
- |
- |
429 |
- |
429 |
|
Total comprehensive (loss)/income for the period |
|
- |
- |
429 |
- |
429 |
|
Share-based payment charges |
|
132 |
- |
- |
- |
132 |
|
Transactions with owners |
|
132 |
- |
- |
- |
132 |
|
Balance at June 30, 2023 |
|
594 |
(126,912) |
(1,098) |
(40) |
(127,456) |
|
The share-based payment reserve arises from the requirement to fair value the issue of share options at grant date. Further details of share options are included at Note 25.
The currency translation reserve represents cumulative foreign exchange differences arising from the translation of the financial statements of foreign subsidiaries and is not distributable by way of dividends.
In June 2022, HeiQ Chrisal N.V. declared and paid a dividend of €470,000 (approximately US$496,000) of which 49% or US$243,000 was paid to minority shareholders.
The Group received in 2022 a capital contribution from a minority shareholder of US$764,000 which arose from a waived loan.
The Group's borrowings are held at amortized cost. They consist of the following:
|
As at |
As at |
Borrowings |
US$'000 |
US$'000 |
Unsecured bank loans |
8,533 |
3,573 |
Secured bank loans |
213 |
628 |
Loans from non-controlling interest |
591 |
137 |
Total borrowings |
9,337 |
4,338 |
The other principal features of the Group's borrowings are as follows:
A credit facility amounting to CHF 2,400,000 (US$2,574,000) was taken out in December 2022 which incurs interest at a fixed rate of 2.2%. It was repaid on February 28, 2023 and the loan was replaced with a new credit facility worth CHF 4,500,000 (US$ 4,964,000).
Several loans amounting to US$1.6 million were assumed through the acquisition of Chrisal. They finance the acquisition of property, plant and equipment as well as the prepayment of provisional taxes. A further €277,000 was taken out in February 2023 which is repayable over ten years. As at June 30, 2023, a total of €1,271,000 (US$1,387,000) is outstanding (December 2022: €938,000 (US$999,000)). The loans are repayable over a period of up to ten 10 years. These loans all have fixed interest rates between 0.78 and 3.95% and the weighted average fixed interest rate on the outstanding balances is 2.85%.
A loan is payable to a minority shareholder of Life-Materials Latam Ltda, Brazil. Interest is fixed at 0.5%. There is no specific repayment date, but the loan is payable once the entity is able to repay it. The balance was BRL 1,020,000 (approximately US$210,000) as at June 30, 2023 (December 31, 2022 is BRL 715,683 (US$137,000).
A bank loan taken out in October 2020 which incurs interest at a fixed rate of 3.25% and which is secured on property owned by a company which is controlled by a minority shareholder of HeiQ Medica. It is repayable in equal monthly instalments of €8,000 (US$9,500) over eight years up to September 2028. As at June 30, 2023, €542,500 (US$592.000) is outstanding (December 31, 2022: US$629,000).
The following table provides a reconciliation of the Group's future maturities of its total borrowings for each year presented:
|
As at |
As at |
Maturity of borrowings |
US$'000 |
US$'000 |
Not later than one year |
7,471 |
2,893 |
Later than one year but less than five years |
721 |
1,029 |
After more than five years |
1,145 |
416 |
Total borrowings |
9,337 |
4,338 |
The following are the major deferred tax liabilities and assets recognized by the Group and movements thereon during the current and prior reporting period.
|
Pension fund obligations |
Tax losses |
Share-based payments |
Capital allowances, depreciation and other temporary differences |
Total |
Deferred tax |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Balance at January 1, 2022 |
429 |
178 |
85 |
(1,686) |
(994) |
Charge to profit or loss |
49 |
(150) |
1 |
681 |
581 |
Charge to other comprehensive income |
(276) |
- |
- |
- |
(276) |
Foreign currency differences |
(12) |
(28) |
5 |
9 |
(26) |
Balance as at December 31, 2022 |
190 |
- |
91 |
(996) |
(715) |
Charge to profit or loss |
9 |
- |
25 |
117 |
151 |
Business combinations |
- |
- |
- |
(201) |
(201) |
Foreign currency differences |
6 |
- |
1 |
- |
7 |
Balance as at June 30, 2023 |
205 |
- |
117 |
(1,080) |
(758) |
Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:
|
|
As at |
|
As at |
Deferred tax |
|
US$'000 |
|
US$'000 |
Deferred tax assets |
|
579 |
|
538 |
Deferred tax liabilities |
|
(1,337) |
|
(1,253) |
Net deferred tax assets (liabilities) |
|
(758) |
|
(715) |
Deferred tax liabilities related to capital allowances and depreciation decreased following the amortization of intangible assets acquired in the business combinations in 2021.
Other non-current liabilities |
As at June 30, 2023 US$'000 |
As at US$'000 |
Defined benefit obligation IAS 19 Switzerland |
1,023 |
952 |
Defined benefit obligation IAS 19 Thailand |
130 |
134 |
Contract liabilities |
4,233 |
3,614 |
Deferred grant income |
386 |
14 |
Total other non-current liabilities |
5,772 |
4,714 |
|
As at June 30, 2023 |
As at December 31, 2022 |
Trade and other payables |
US$'000 |
US$'000 |
Trade payables |
6,086 |
3,321 |
Payables to tax authorities |
326 |
375 |
Other payables |
2,241 |
1,626 |
Total trade and other payables |
8,653 |
5,322 |
Trade payables principally comprise amounts outstanding for trade purchases and ongoing costs. Other payables relate to employee-related expenses, utilities and other overhead costs. Typically, no interest is charged on the trade payables. The Group has financial risk management policies in place to ensure that all payables are paid within the pre-agreed credit terms.
The directors consider that the carrying amount of trade payables approximates to their fair value.
|
As at June 30, 2023 |
As at December 31, 2022 |
Accrued liabilities |
US$'000 |
US$'000 |
Costs of goods sold |
909 |
875 |
Personnel expenses |
1,415 |
1,737 |
Other operating expenses |
1,368 |
2,366 |
Total accrued liabilities |
3,692 |
4,978 |
|
As at June 30, 2023 |
As at December 31, 2022 |
Deferred revenue |
US$'000 |
US$'000
|
Contract liabilities |
1,230 |
1,176 |
Prepayments for unshipped goods |
80 |
94 |
Deferred grant income |
55 |
15 |
Total deferred revenue |
1,365 |
1,285 |
|
As at June 30, 2023 |
As at December 31, 2022 |
Contract liabilities |
US$'000 |
US$'000 |
Exclusivity agreements |
1,585 |
1,832 |
Research and development services |
3,878 |
2,958 |
Total contract liabilities |
5,463 |
4,790 |
Current liabilities (Note 32) |
1,230 |
1,176 |
Non-current liabilities (Note 29) |
4,233 |
3,614 |
Total contract liabilities |
5,463 |
4,790 |
Revenue relating to both exclusivity and research and development services is recognized over time although the customer pays up-front in full for these services. A contract liability is recognized for revenue relating to the services at the time of the initial sales transaction and is released over the service period.
|
As at June 30, 2023 |
As at December 31, 2022 |
Current liabilities |
US$'000 |
US$'000 |
Deferred consideration in relation to acquisitions |
92 |
92 |
Call option liability |
453 |
686 |
Other current liabilities |
545 |
778 |
On October 10, 2022 the Group announced that it has filed a complaint in the United States District Court for the Western District Of North Carolina, Charlotte Division, against ICP Industrial Inc, for breaching its Exclusive Agreement terms. Because of the claimed contract breach, the Group has not recognized any income or assets from the contract. Within the same legal proceeding, ICP Industrial Inc, has filed a counter claim against the Group. Although the Group is confident in its legal position, the outcome of the legal proceedings as well as the court-mandated mediation remains uncertain. Therefore, while a future economic benefit is expected, it can not be reliably quantified at this point in time and could bear the risk of prejudice given the ongoing legal proceedings.
Provisions |
|
As at June 30, 2023 US$'000 |
As at December 31, 2022 US$'000 |
|
Current liabilities |
|
- |
339 |
|
Non-current liabilities |
|
- |
- |
|
Total provisions |
|
- |
339 |
|
|
Legal/Compliance provision |
Total |
||
Current liabilities |
US$'000 |
US$'000 |
||
Balance at January 1, 2022 |
- |
- |
||
Additional provision in the year |
339 |
339 |
||
Utilization of provision |
- |
- |
||
Exchange difference |
- |
- |
||
Balance as at December 31, 2022 |
339 |
339 |
||
Additional provision in the period |
- |
- |
||
Utilization of provision |
(339) |
(339) |
||
Exchange difference |
- |
- |
||
Balance as at June 30, 2023 |
- |
- |
||
The Group was contacted by the United States Environmental Protection Agency ("EPA") in connection with violations of the Federal Insecticide, Fungicide and Rodenticide Act ("FIFRA") pertaining to mislabelling. As at December 31, 2022, the Company has assessed the claim and made a provision for US$339,000 which was paid in May 2023.
This provision is reported in Note 31 as Accrued liabilities - Other operating expenses.
Certain shares were issued during the year for a non-cash consideration as described in Note 24.
During the year ended December 31, 2022, additions to buildings and land amounting to US$1,862,000 million were financed by issuing shares.
The Company defines working capital as trade receivables, other receivables and prepayments less trade and other payables, accrued liabilities and deferred revenue.
Six months ended June 30, 2023 |
Opening balances |
Assumed on acquisition of subsidiaries |
Change in balance |
Closing balances |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
||
Inventories |
|
13,168 |
13 |
1,225 |
14,406 |
Trade receivables |
|
6,487 |
11 |
1,758 |
8,256 |
Other receivables and prepayments |
|
4,262 |
12 |
(43) |
4,231 |
Trade and other receivables and prepayments |
|
10,749 |
23 |
1,715 |
12,487 |
Trade and other payables |
|
5,322 |
- |
3,331 |
8,653 |
Accrued liabilities |
|
4,978 |
- |
(1,286) |
3,692 |
Deferred revenue incl. non-current contract liabilities |
|
4,913 |
- |
1,072 |
5,985 |
Trade and other payables, accrued liabilities and deferred revenue |
15,213 |
- |
3,117 |
18,330 |
Six months ended June 30, 2022 |
Opening balances |
Assumed on acquisition of subsidiaries |
Change in balance |
Closing balances |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
||
Inventories |
|
13,770 |
- |
2,414 |
16,184 |
Trade receivables |
|
14,656 |
- |
3,462 |
18,118 |
Other receivables and prepayments |
|
3,876 |
- |
(1,854) |
2,022 |
Trade and other receivables and prepayments |
|
18,532 |
- |
1,608 |
20,140 |
Trade and other payables |
|
8,271 |
- |
(1,312) |
6,959 |
Accrued liabilities |
|
3,386 |
- |
(1,208) |
2,178 |
Deferred revenue incl. non-current contract liabilities |
|
1004 |
- |
4,968 |
5,972 |
Trade and other payables, accrued liabilities and deferred revenue |
12,661 |
- |
2,448 |
15,109 |
Year ended December 31, 2022 |
Opening balances |
Assumed on acquisition of assets |
Change in balance |
Closing balances |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
||
Inventories |
|
13,770 |
- |
(602) |
13,168 |
Trade receivables |
|
14,656 |
- |
(8,169) |
6,487 |
Other receivables and prepayments |
|
3,876 |
- |
386 |
4,262 |
Trade and other receivables and prepayments |
18,532 |
- |
(7,783) |
10,749 |
|
Trade and other payables |
|
8,271 |
- |
(2,949) |
5,322 |
Accrued liabilities |
|
3,386 |
9 |
1,583 |
4,978 |
Deferred revenue incl. non-current contract liabilities |
|
1,004 |
- |
3,909 |
4,913 |
Trade and other payables, accrued liabilities and deferred revenue |
12,661 |
9 |
2,543 |
15,213 |
Six months ended June 30, 2023 |
|
US$'000 |
Consideration payment for acquisition of Tarn Pure |
|
621 |
Cash assumed on acquisition of Tarn Pure |
|
(2) |
Net consideration payment for acquisitions of businesses and assets |
|
619 |
Year ended December 31, 2022 |
|
US$'000 |
Consideration payment for acquisition of Life Materials Technologies Ltd |
|
1,400 |
Consideration payment for acquisition of ChemTex assets |
|
187 |
Net consideration payment for acquisitions of businesses and assets |
|
1,587 |
The Group have not identified any significant transactions with related parties. There are no loans outstanding with related parties.
As communicated on July 06, 2023, HeiQ Plc sold a 1.5% minority interest in HeiQ AeoniQ GmbH to MAS Holdings for US$1.5 million. It was also agreed that a further 1% shareholding will be sold to MAS Holdings for US$1 million subject to the achievement of a mutually agreed milestone.
As at June 30, 2023, the Company did not have any single identifiable controlling party.